Freenome has raised $1.1B in total across 6 funding rounds.
Freenome's investors include Anzu Partners, Ameena El-Bibany, Vasudev Bailey, Artis Ventures (AV), Asset Management Ventures, Bain Capital Life Sciences, Cofounders Capital, Merck Global Health Innovation Fund, Polaris Partners, RA Capital, Section 32, Anne Wojcicki.
Freenome is a biotechnology company developing non-invasive blood tests for early cancer detection using multiomics technology and machine learning.[1][2][4] Its platform analyzes genomic, epigenomic, proteomic, and other biomarkers from blood samples to identify cancers like colorectal, lung, breast, and prostate at treatable stages, serving patients, physicians, and healthcare providers to enable proactive screening and reduce cancer mortality.[1][2][6] The company targets colorectal cancer (CRC) with its first commercial product via an exclusive license with Exact Sciences, while expanding to multi-cancer detection, backed by $1.35 billion in funding, over 530 employees, and ongoing clinical trials like PREEMPT CRC.[4][7]
Founded in 2014, Freenome emerged from the need for non-invasive early cancer detection through liquid biopsies on blood samples.[1][3][4] Co-founders include Gabe Otte (CEO) and Riley Ennis (Chief Product Officer), who combined expertise in machine learning, biology, and computer science to build adaptive genomics engines that decode complex signals beyond traditional mutations, such as immunological and metabolic changes in cell-free DNA.[5][7] Early traction came from collaborations with over 25 research partners like UC San Diego, UCSF, and Massachusetts General Hospital, processing thousands of samples, and partnerships with five pharmaceutical companies for trial validation, leading to Series A extensions and rapid scaling.[5]
Freenome rides the precision oncology wave, where AI-driven liquid biopsies shift cancer care from reactive treatment to preventive screening amid rising global cancer burdens.[1][2][8] Timing aligns with NGS advancements, regulatory pushes for blood-based tests, and post-pandemic demand for non-invasive diagnostics, amplified by partnerships like Exact Sciences for real-world data and scale.[7] It influences the ecosystem by validating novel biomarkers, enabling pharma trial stratification, and pushing multi-cancer platforms, potentially expanding to non-cancer diseases while competing in the $10B+ MCED market.[4][5][7]
Freenome is poised for FDA submissions, CRC commercialization via Exact Sciences, and 2026 lung test launch, with expansion to personalized MCED panels using risk-based AI classifiers.[4][7] Trends like real-world evidence integration, insurer coverage for preventive screening, and AI interpretability will accelerate growth, evolving its influence from CRC pioneer to broad disease detection leader. This builds on its core mission, outpacing cancer through accessible blood tests that transform global outcomes.[2][8]
Freenome has raised $1.1B across 6 funding rounds. Most recently, it raised $250.0M Venture Round in February 2024.
